Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, addition to baseline treatment, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of Satralizumab (SA237) in patients with Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Next Previous
X
Search
Trial Profile

A multicenter, randomized, addition to baseline treatment, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of Satralizumab (SA237) in patients with Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Satralizumab (Primary)
  • Indications Neuromyelitis optica
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Acronyms SAkuraSky
  • Sponsors Roche

    • Most Recent Events

    • 24 Aug 2022 Planned number of patients changed from 70 to 85.
    • 26 Apr 2022 Results from SAkuraSky and SAkuraStar assessing the long-term efficacy of satralizumab in patients with aquaporin-4-immunoglobulin-G-seropositive NMOSD, presented at the 74th Annual Meeting of the American Academy of Neurology 2022
    • 26 Apr 2022 Results of two studies (SAkuraSky and SAkuraStar) assessing long-term safety of satralizumab in patients (pts) with NMOSD during the double-blind periods and open-label extensions of the SAkura studies, presented at the 74th Annual Meeting of the American Academy of Neurology 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top